Genome editing of SNAI1 gene in rhabdomyosarcoma: a novel model for studies of its role
Abstract: Genome editing (GE) tools and RNA interference technology enable the modulation of gene expression in cancer research. While GE mediated by clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 or transcription activator-like effector nucleases (TALEN) activity can be used to induce gene knockouts, shRNA interacts with the targeted transcript, resulting in gene knockdown. Here, we compare three different methods for SNAI1 knockout or knockdown in rhabdomyosarcoma (RMS) cells. RMS is the most common sarcoma in children and its development has been previously associated with SNAI1 transcription factor activity. To investigate the role of SNAI1 in RMS development, we compared CRISPR/Cas9, TALEN, and shRNA tools to identify the most efficient tool for the modulation of SNAI1 expression with biological effects. Subsequently, the genome sequence, transcript levels, and protein expression of SNAI1 were evaluated. The modulation of SNAI1 using three different approaches affected the morphology of the cells and modulated the expression of myogenic factors and HDAC1. Our study revealed a similar effectiveness of the tested methods. Nevertheless, the low efficiency of the GE tools was a limiting factor in obtaining biallelic gene knockouts. To conclude, we established and characterized three different models of SNAI1 knockout and knockdown that might be used in further studies investigating the role of SNAI1 in RMS
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
Cells. - 9, 5 (2020) , 1095, ISSN: 2073-4409
- Schlagwort
-
Rhabdomyosarkom
Genome Editing
CRISPR/Cas-Methode
- Ereignis
-
Veröffentlichung
- (wo)
-
Freiburg
- (wer)
-
Universität
- (wann)
-
2020
- Urheber
-
Ulman, Aleksandra
Skrzypek, Klaudia
Konieczny, Pawel
Mussolino, Claudio
Cathomen, Anton
Majka, Marcin
- DOI
-
10.3390/cells9051095
- URN
-
urn:nbn:de:bsz:25-freidok-1663595
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
19.03.2025, 00:00 MEZ
Datenpartner
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Ulman, Aleksandra
- Skrzypek, Klaudia
- Konieczny, Pawel
- Mussolino, Claudio
- Cathomen, Anton
- Majka, Marcin
- Universität
Entstanden
- 2020
Ähnliche Objekte (12)
Clinical genome editing to treat sickle cell disease - a brief update
Establishing a zinc finger nuclease platform for targeted genome editing in human cell lines, primary keratinocyte stem cells and cardiomyocytes in vivo
Pre-clinical development of HIV resistant genome edited human CD4+ T cells
Targeted genome editing restores T cell differentiation in a humanized X-SCID pluripotent stem cell disease model
Entwicklung von gentechnologischen Strategien zur Überwindung der Bluthirnschranke am Modell des Morbus Gaucher Typ 2
TALENs facilitate targeted genome editing in human cells with high specificity and low cytotoxicity
Targeted gene transfer to enhance safety and efficacy of immunotherapy
Generation of safe CAR T cells to target B cell malignancies
A novel Cas9 fusion protein promotes targeted genome editing with reduced mutational burden in primary human cells
Editing the core region in HPFH deletions alters fetal and adult globin expression for treatment of [beta]-hemoglobinopathies
Progress and harmonization of gene editing to treat human diseases: Proceeding of COST Action CA21113 GenE-HumDi
Hijacking-DNA -Repair (HDR)-CRISPR promotes seamless gene editing in human primary cells
Clinical genome editing to treat sickle cell disease - a brief update
Establishing a zinc finger nuclease platform for targeted genome editing in human cell lines, primary keratinocyte stem cells and cardiomyocytes in vivo
Pre-clinical development of HIV resistant genome edited human CD4+ T cells
Targeted genome editing restores T cell differentiation in a humanized X-SCID pluripotent stem cell disease model
Entwicklung von gentechnologischen Strategien zur Überwindung der Bluthirnschranke am Modell des Morbus Gaucher Typ 2
TALENs facilitate targeted genome editing in human cells with high specificity and low cytotoxicity
Targeted gene transfer to enhance safety and efficacy of immunotherapy
Generation of safe CAR T cells to target B cell malignancies
A novel Cas9 fusion protein promotes targeted genome editing with reduced mutational burden in primary human cells
Editing the core region in HPFH deletions alters fetal and adult globin expression for treatment of [beta]-hemoglobinopathies
Progress and harmonization of gene editing to treat human diseases: Proceeding of COST Action CA21113 GenE-HumDi
Hijacking-DNA -Repair (HDR)-CRISPR promotes seamless gene editing in human primary cells
Clinical genome editing to treat sickle cell disease - a brief update
Establishing a zinc finger nuclease platform for targeted genome editing in human cell lines, primary keratinocyte stem cells and cardiomyocytes in vivo
Pre-clinical development of HIV resistant genome edited human CD4+ T cells
Targeted genome editing restores T cell differentiation in a humanized X-SCID pluripotent stem cell disease model
Entwicklung von gentechnologischen Strategien zur Überwindung der Bluthirnschranke am Modell des Morbus Gaucher Typ 2
TALENs facilitate targeted genome editing in human cells with high specificity and low cytotoxicity
Targeted gene transfer to enhance safety and efficacy of immunotherapy
Generation of safe CAR T cells to target B cell malignancies
A novel Cas9 fusion protein promotes targeted genome editing with reduced mutational burden in primary human cells
Editing the core region in HPFH deletions alters fetal and adult globin expression for treatment of [beta]-hemoglobinopathies
Progress and harmonization of gene editing to treat human diseases: Proceeding of COST Action CA21113 GenE-HumDi